The DurAVR THV. [Image from Anteris Technologies]Anteris Technologies today announced the launch of its initial public offering in the U.S.

DurAVR THV。[安泰瑞斯科技图片]安泰瑞斯科技今天宣布在美国启动首次公开募股。

The company aims to raise funds through the IPO to advance the development of its DurAVR transcatheter heart valve technology.

该公司旨在通过IPO筹集资金，以推动其DurAVR经导管心脏瓣膜技术的发展。

Anteris’ IPO consists of 14.8 million shares of common stock, with an additional 2.22 million shares available to underwriters under a 30-day option. The company has applied to list its shares on the Nasdaq Global Market under the AVR ticker.

Anteris的首次公开募股由1480万股普通股组成，另外222万股可根据30天期权提供给承销商。该公司已申请在纳斯达克全球市场以AVR股票代码上市。

Proceeds from the IPO will primarily support the development of the DurAVR transcatheter heart valve and the start of a global pivotal study that will target severe aortic stenosis treatment. Any remaining funds will be allocated to working capital, corporate purposes, and the repayment of convertible note facility obligations..

IPO的收益将主要支持DurAVR经导管心脏瓣膜的开发，以及针对严重主动脉瓣狭窄治疗的全球关键研究的开始。任何剩余资金将用于营运资金、公司用途以及偿还可转换票据贷款义务。。

More about Anteris’ technology

有关Anteris技术的更多信息

The DurAVR is a transcatheter heart valve Anteris designed to treat aortic stenosis. It is one of the first transcatheter aortic valve replacements to use a single piece of bioengineered tissue. The biomimetic valve is shaped to replicate the performance of a healthy human aortic valve.

DurAVR是一种经导管心脏瓣膜，旨在治疗主动脉瓣狭窄。它是第一个使用单一生物工程组织的经导管主动脉瓣置换术之一。仿生瓣膜的形状可以复制健康人主动脉瓣的性能。

DurAVR is made using Anteris’ patented anti-calcification tissue technology, Adapt Tissue. Adapt has been used clinically for over 10 years and is distributed to over 55,000 patients worldwide.

DurAVR采用Anteris获得专利的抗钙化组织技术Adapt tissue制造。Adapt已在临床上使用了10多年，并在全球范围内分发给55000多名患者。

According to the company, the heart valve is delivered through the ComASUR Delivery System, which provides controlled deployment and accurate placement with balloon-expandable delivery. Anteris designed the delivery system to achieve precise alignment with the heart’s native commissures to achieve ideal valve positioning..

据该公司称，心脏瓣膜是通过ComASUR输送系统输送的，该系统通过球囊扩张输送提供受控部署和准确放置。Anteris设计了输送系统，以实现与心脏天然连合的精确对齐，从而实现理想的瓣膜定位。。